Globus Medical (GMED) is a musculoskeletal expertise firm that crushed Q1 estimates and is using one of many strongest earnings revision cycles within the med-device house. GMED earns a Zacks Rank #1 (Sturdy Purchase) and is immediately’s Bull of the Day.
Concerning the Firm
Headquartered in Audubon, PA, Globus Medical is a medical system firm targeted on musculoskeletal issues, with greater than 209 merchandise distributed throughout 65 nations worldwide.
The portfolio breaks into two classes:
Musculoskeletal Options covers implants, biologics, and surgical devices for backbone, trauma, and joint reconstruction, and drove 95% of 2025 revenues with 18% progress from the prior yr.
Enabling Applied sciences encompasses the corporate’s robotic, navigation, and imaging-assisted surgical procedure platform designed to make advanced procedures safer and extra reproducible.
GMED is valued at $10 billion and has a Ahead PE of 17. The inventory has Zacks Fashion Scores of “B” in Worth, however “A” in Progress and Momentum.
Q1 Earnings Beat
Globus delivered a powerful quarter, with EPS of $1.12, above the $0.92 estimate. This 22% backside line beat got here whereas income of $759.9 million grew 27% yr over yr and topped the $730 million consensus. Adjusted EBITDA of $245.3 million expanded the margin to 32.3% from 29.7% a yr in the past. Margins rising quicker than gross sales is a uncommon mixture at this scale.
Administration raised full-year non-GAAP EPS steering to $4.70–$4.80 from $4.40–$4.50 whereas holding the income vary regular at $3.18–$3.22 billion. The EPS increase on an unchanged gross sales information alerts the margin enlargement is structural, not a one-quarter occasion.
Globus Medical, Inc. Value and EPS Shock
Globus Medical, Inc. price-eps-surprise | Globus Medical, Inc. Quote
Estimates Head Larger
Analysts have been elevating estimates for the reason that earnings launch. Over the past 30 days estimates have moved from $1.02 to $1.09, a leap of seven%
Wanting on the bigger time frames, current-year EPS consensus sat at $3.89 simply 90 days in the past. It is now $4.66, which is a 20% transfer larger in a single quarter.
Subsequent yr moved from $4.11 to $5.05 over the identical window, an enormous transfer of 23%
After earnings Wedbush reiterated its Outperform and $103 goal.
The Diver
US Backbone is the engine. Three straight quarters of roughly 10% progress, 58 consecutive weeks of good points, in a market the corporate estimates are solely rising 3%. The gross margin story is equally compelling: 69.2% in Q1, flat with This fall regardless of the seasonal income step-down, and the sixth straight quarter of sequential enchancment. Administration’s long-term goal is the mid-70s.
Product catalysts are lined up. SCRIPPT patient-specific spacers and rods cleared the FDA in early Q2. ANTHEM elbow plating demand is working forward of provide. The robotics put in base is rising via a lease-and-rental mannequin constructed to generate recurring implant and repair income for years.
The Drag
The acquired Nevro SCS enterprise stays in restructuring. Administration stated it probably “will get a bit worse earlier than it will get higher” with restoration back-half loaded. That is the explanation full-year income steering was held flat regardless of the Q1 beat. However with the bottom enterprise absorbing the drag and nonetheless increasing margins quicker than gross sales, Nevro is a timing situation, not a thesis downside.
That drag is the primary motive the inventory bought off after the EPS launch, however this seems to be like an enormous shopping for alternative.
The Technical Take
Late final yr the inventory gapped larger after a blowout quarter, shifting from $60 to $80. Since then, the inventory has been buying and selling across the $90 degree till it dropped beneath $75 after earnings.
That $75 space is the 61.8% retracement and has held assist. The inventory has since bounced again to the 200-day shifting common at $79. Let’s have a look at these shifting averages
21-day: $86
50-day: $87.50
200-day: $79
If the latest lows maintain up, the bulls might want to push larger and get above the 50-day MA, fill that earnings transfer hole after which resume the development.
In Abstract
GMED is a Zacks #1 Ranked inventory with a 90-day estimate revision cycle that rivals something in healthcare, a margin construction that retains increasing, and a home backbone franchise taking share at triple the market progress fee.
With the inventory exhibiting shopping for at technical assist, GMED seems to be like a long-term purchase at present ranges.
Radical New Expertise Might Hand Traders Enormous Beneficial properties
Quantum Computing is the following technological revolution, and it could possibly be much more superior than AI.
Whereas some believed the expertise was years away, it’s already current and shifting quick. Giant hyperscalers, corresponding to Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to combine quantum computing into their infrastructure.
Senior Inventory Strategist Kevin Cook dinner reveals 7 rigorously chosen shares poised to dominate the quantum computing panorama in his report, Past AI: The Quantum Leap in Computing Energy.
Kevin was among the many early consultants who acknowledged NVIDIA’s monumental potential again in 2016. Now, he has keyed in on what could possibly be “the following massive factor” in quantum computing supremacy. Immediately, you might have a uncommon likelihood to place your portfolio on the forefront of this chance.
See High Quantum Shares Now >>
Globus Medical, Inc. (GMED) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
